John Andrew Boockvar, MD
Vice Chair, Department of Neurosurgery
Lenox Hill Hospital
Director, Brain Tumor and Pituitary/ Neuroendocrine Center
Lenox Hill Hospital & Manhattan Eye, Ear and Throat Hospital
Investigator, Laboratory for Brain Tumor Biology
The Feinstein Institute for Medical Research
Professor, Neurosurgery and Otolaryngology/Head and Neck Surgery
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Dr. Boockvar is the Vice Chair of the Department of Neurosurgery at Lenox Hill Hospital and Director of the Brain Tumor Center, and the Pituitary/Neuroendocrine Center of the Department of Neurosurgery and the New York Head and Neck Institute at Lenox Hill and Manhattan Eye, Ear and Throat Hospitals. Dr. Boockvar is a Professor of Neurological Surgery and Otolaryngology/Head and Neck Surgery at the Zucker School of Medicine. Dr. Boockvar is an investigator at the Feinstein Institute for Medical Research where he directs the Laboratory for Brain Tumor Biology and Therapy.
Dr. Boockvar is internationally known for his surgical expertise and for providing patients with safe, effective, and minimally invasive treatment for brain tumors, skull base disorders, and disorders of the spine. Dr. Boockvar's surgical expertise is in benign and malignant brain tumors, skull base and endoscopic pituitary surgery, spinal and peripheral nerve tumors, minimally invasive spinal surgery, and complex spinal disorders. Dr. Boockvar has been recognized for his novel research in brain tumors and stem cell biology. Dr. Boockvar has been repeatedly named to the lists of New York Magazine’s Top Docs, Best Doctors in New York-Castle Connolly, New York SuperDoctors , America's Top Surgeons, America's Best Doctors, and America's Best Doctors for Cancer. His research has been widely published and he has received numerous national awards including the Eric Lichtenstein Humanitarian Award from Voices Against Brain Cancer for his compassionate work in treating patients with brain cancer. In 2016 Dr. Boockvar was elected to the prestigious Academy of Neurological Surgeons. In 2017 he was elected to the Senior Society of the American Board of Neurological Surgery.
Dr. Boockvar has been repeatedly featured on CNN, ABC, CNBC, CBS, and Fox News Channel, and has appeared on The Dr. Oz Show as well as in the New York Times, New York Daily News, and Crain's Business Journal among others. Dr. Boockvar was a featured neurosurgeon on the ABC hit show NY MED. In 2016, He was one of only two neurosurgeons in the nation to be featured in the documentary “Surviving Terminal Cancer”. Most recently, Dr. Boockvar was featured on a special episode of the Dr. Oz Show on brain tumors, Good Morning America and the Today Show with Megyn Kelly. Dr. Boockvar is also an honorary surgeon of the NYPD and the New York State Troopers. Click here to view Dr. Boockvar's Wikipedia page.
Training and Experience
Dr. Boockvar received a B.A from the University of Pennsylvania. Like his father, grandfather, and great-grandfather before him, Dr. Boockvar received an M.D. from SUNY Brooklyn-Downstate Medical Center. Dr. Boockvar graduated summa cum laude with Distinction in Research and was medical school class valedictorian. Dr. Boockvar did his surgical internship and neurosurgical residency at the Hospital of the University of Pennsylvania. Dr. Boockvar did his NIH-supported post-doctoral research training in Neuro-oncology at the University of Pennsylvania Cancer Center. At Penn, Dr. Boockvar received the prestigious Ruth Kirstein NRSA award for his research into stem cell biology and malignant brain tumors. He also directed the University of Pennsylvania pituitary and skull base laboratory and completed a dedicated complex spine surgery fellowship. After leaving Penn, Dr. Boockvar completed an National Cancer Institute funded Mentored Career Development Award under Eric Holland, MD and Shahin Rafi, MD at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, respectively. Immediately prior to joining Northwell, Dr. Boockvar was Professor of Neurological Surgery at Weill Cornell Medical College/ New York Presbyterian Hospital. At Weill Cornell, Dr. Boockvar was Co-Director of Neurosurgical Oncology, Head of the Laboratory for Translational Stem Cell Research and Director of the Brain Tumor Research Group.
Dr. Boockvar currently co-directs the Laboratory for Brain Tumor Biology and Therapy at the Feinstein Institute for Medical Research. His laboratory interests have focused on adult human neural stem cell biology as it relates to brain tumor formation and resistance to therapy. Dr. Boockvar is a world expert on blood brain barrier disruption to improve the delivery of therapeutics to the human brain. Dr. Boockvar is the principal investigator of several cutting edge clinical trials using blood brain barrier disruption to deliver high dose chemotherapy for patients with malignant brain tumors that have been featured in the New York Times and Wall Street Journal. Dr. Boockvar has served as Editor-in-Chief of the journal Current Stem Cell Research and Therapy and is an editorial board member of the Journal of Neuro-Oncology, Neurosurgery, Journal of Neurosurgery, and Recent Patents on Anti-Cancer Drug Discovery. Dr. Boockvar directs the Brain Tumor Biotech Center at the Institute that seeks to bridge the translational gap between basic and clinical science for patients with malignant brain tumors. Dr. Boockvar's laboratory has been funded by the National Institutes of Health and he was recently awarded the American Association of Neurological Surgeons Pinnacle Partners Award for his research into brain tumors. He has also won research awards from Voices Against Brain Cancer, the American Brain Tumor Association, the Starr Foundation, Anspach Companies, and the Adelson Foundation.
In the News
In 2007, Dr. Boockvar received acclaim for helping to save a window washer who had fallen 47 stories. By operating on both his brain and spinal cord, Dr. Boockvar not only saved the man's life but helped him to walk again and regain normal functioning (see The New York Times article about the surgery, as well as a 2014 update on the patient in the New York Post). Dr. Boockvar has been on the cover of The New York Times Science Times twice. On November 9, 2010, the anniversary issue of the Science Times asked science reporters and top researchers to provide their watch list for noteworthy advances in 2011 and to identify which "fields are hot." This list included Dr. Boockvar and the studies he is conducting for people with Glioblastoma Multiforme (see article). Most recently, Dr. Boockvar was featured on a special episode of the Dr. Oz Show on brain tumors, Good Morning America and the Today Show with Megyn Kelly.
PI: John Boockvar, MD
The purpose of this research study is to confirm the effectiveness and safety of osilodrostat in treating patients with Cushing’s disease. Osilodrostat is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA). The safety of the osilodrostat is being tested at different dose levels. Twelve patients with Cushing’s disease have been treated with this study drug for 10 weeks and nineteen patients have been treated for 22 weeks. Results showed that osilodrostat was effective in reducing the cortisol level in all of them. In addition, another large study is ongoing, in which patients will receive osilodrostat for up to 96 weeks.
Osilodrostat is a potent, oral inhibitor of 11β-hydroxylase (CYP11B1), the enzyme that catalyzes the last step in the biosynthesis of cortisol. The current development activity of osilodrostat is focused on the treatment of patients with Cushing’s disease (hypercortisolism due to a pituitary corticotroph adenoma), because it is the most common cause of Cushing’s syndrome and it is a relatively homogeneous patient group. This drug also inhibits aldosterone synthase (CYP11B2), and therefore is a dual inhibitor of both cortisol and aldosterone synthesis. This study is sponsored by the pharmaceutical company named Novartis. Around 69 patients will join this study in approximately 35 centers located in different countries (around 12) across the world.
PI: John Boockvar, MD
The purpose of this research study is to test the safety and tolerability of a new investigational study drug called EGFR(V)-EDV-Dox in the treatment of recurrent glioblastoma multiforme (GBM). EGFR(V)-EDV-Dox is made up of three parts:
- The EnGeneIC Delivery Vehicle (EDV). The EDVs are particles made from modified Salmonella bacteria. The type of Salmonella used to make EDVs is one that does not cause disease.
- Chemotherapy, in this case doxorubicin, is packaged inside the EDVs.
- The EDVs are then coated with a protein called anti-EGFR bispecific antibody. The anti-EGFR bispecific antibody is based on part of the Vectibix® antibody sequence.
EDVs are a new way of delivering drugs for the treatment of cancer because they can be delivered directly to the tumor site. The EDVs attach to epidermal growth factor receptor (EGFR) on the cancer cells. After attaching to the EGFR receptor, the EDVs are taken up inside the cancer cells, and the chemotherapy is delivered directly into the cancer itself. EGFR(V)-EDV-Dox is not approved by the Food and Drug Administration (FDA). Doxorubicin is approved by the FDA for the treatment of more than 10 different types of cancers. It is not approved for use in GBM. Vectibix® is approved by the FDA for the treatmentof some forms of colorectal cancer. It is not approved for use in GBM. The FDA is allowing the use of doxorubicin and a bispecific antibody based on the Vectibix® antibody sequence in this study. A study of EGFR(V)-EDV-Dox in humans has been completed in Australia, and overall the study drug was well tolerated. In this study we want to see if multiple doses of the study drug at two dose levels are safe, and to monitor the side effects (if there are any) at each of these 2 dose levels.
PI: John Boockvar, MD
The purpose of this study is to test the safety, tolerability and efficacy of disulfiram and copper gluconate, in combination with temozolomide in the treatment of recurrent glioblastoma multiforme (GBM). Disulfiram (DSF) is a FDA-approved oral medication that has been used for treating alcoholism since 1951. It inhibits aldehyde dehydrogenase (ALDH), which leads to accumulation of acetaldehyde in the blood after ingestion of alcohol. It has well-known safety profile for up to 3000 mg per day in the absence of alcohol consumption and has been shown to readily cross the blood-brain barrier. Copper gluconate is a dietary food supplement. The combination of the two drugs, in combination with temozolomide (TMZ), is investigational. Preclinical studies have identified DSF-Cu as having promising activity against GBM cells and can potentially re-sensitize TMZ-resistant cells and orthoptic tumors to TMZ again. A special formulation of both disulfiram and copper gluconate are being produced for Cantex, the Sponsor of the study. Temozolomide (Temodar) will be prescribed by oncologists. This clinical trial of TMZ with the addition of DSF-Cu for TMZ-resistant GBM will provide valuable single-agent efficacy data regarding DSF-Cu and could prospectively validate its potential to re-sensitize GBM to TMZ.
PI: John Boockvar, MD
The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an FDA-approved oral chemotherapy for refractory or relapsed metastatic breast cancer, metastatic colon cancer, and in stage III colon cancer. Research has been done to show the combination of capecitabine and temozolomide has successfully treated neuro-endocrine tumors with acceptable side effects. Those studies suggest that capecitabine, when given 10 days ahead of temozolomide, helps the temozolomide work better against the cancer cells. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.
PI: John Boockvar, MD
The purpose of this study is to find out whether intraoperative radiotherapy (IORT) is more effective at preventing tumor re-growth than standard therapy. The technique called "intraoperative radiotherapy" (IORT) to treat the tumor cavity with radiotherapy (x-rays) during surgery is investigational. IORT allows high doses of radiation to be delivered directly to the site of the tumor following craniotomy. IORT delivers a large dose of radiation in a single treatment session, while also working to preserve more healthy tissue. This may reduce side effects and the need to return to the hospital for radiation treatments. Subjects will be randomized into two groups: 1) craniotomy only or 2) craniotomy and IORT. In group 2, craniotomy will be followed by the application of a radiation-emitting device that will deliver a 20-30 Gy dose of x-rays into the tumor cavity. The primary objective of the study will examine progression free survival rate following treatment. Secondary endpoints include important aspects of loco-regional and global efficiency (OS, patterns of relapse), prognostic factors (age, KPS, MGMT, etc.), as well as quality of life and safety parameters.
PI: John Boockvar, MD
The purpose of this study is to evaluate the safety and efficacy of administering repeated doses of cetuximab into the femoral artery when combined with standard of care oral temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cetuximab belongs to a class of drugs called epidermal growth factor receptor (EGFR) inhibitors. A percentage of malignant brain tumors, such as glioblastoma multiforme and anaplastic astrocytoma, contain amplified and over-expressed EGFR. There have been few previous studies performed at other institutions using cetuximab for malignant brain tumors. This study is unique in that we are delivering cetuximab through a novel delivery method called Superselective Intra-arterial Cerebral Infusion (SIACI). We hope this allows us to deliver a higher dose of cetuximab to the tumor site, while limiting systemic exposure.
PI: John Boockvar, MD
The purpose of this study is to evaluate the safety and efficacy of administering repeated doses of cetuximab into the femoral artery for the treatment of relapsed or refractory glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligoastrocytoma. This study will try to determine the proposed regimen of cetuximab administered into arteries repeatedly with re-irradiation is effective. A superselective intra-arterial dose of cetuximab at 250 mg/m2 will be given on day 1, followed by hypo-fractionated re-radiation 3-5 days later. A second and third dose of superselective intra-arterial cetuximab at 250 mg/m2 will be given around 21 and 90 days respectively. Cetuximab belongs to a class of drugs called epidermal growth factor receptor (EGFR) inhibitors. A percentage of malignant brain tumors, such as glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), contain amplified and over-expressed EGFR. There have been few previous studies performed at other institutions using cetuximab for malignant brain tumors. This study is unique in that we are delivering cetuximab through a novel delivery method called Superselective Intra-arterial Cerebral Infusion (SIACI). We hope this allows us to deliver a higher dose of cetuximab to the tumor site, while limiting systemic exposure.
PI: John Boockvar, MD
Co-PI: Caroline Messer, MD
The purpose of this research study is to determine the best treatment for hyperglycemia that may occur from receiving the study drug, pasierotide, which is being provided for the treatment of Cushing’s disease or acromegaly. In Cushing’s disease, the tumor of the pituitary gland causes the adrenal glands to secrete an excess of cortisol, leading to many of the disease’s harmful effects. Pasireotide reduces the amount of cortisol produced by the adrenal glands. Pasireotide is approved in Europe and in the USA as a subcutaneous formulation (injected beneath the skin) under the trade name Signifor® s.c. for the treatment of people with Cushing’s disease. Acromegaly is characterized by the overproduction of growth hormone (GH) by the pituitary gland. In over 95% of patients with acromegaly, the disease is caused by a GH-secreting pituitary adenoma (benign or non-cancerous tumor in the pituitary gland). Pasireotide has also been developed as a long-acting release formulation (LAR) for the treatment of acromegaly, which acts by reducing the level of growth hormone in the blood. Pasireotide LAR has been approved by the Food and Drug Administration as an intramuscular injection (injected into the muscle) under the trade name Signifor® LAR for the treatment of people with acromegaly. Hyperglycemia was a frequently observed adverse drug reaction during the pasireotide clinical studies. This study is designed to evaluate the safety and effectiveness of incretin based anti-diabetic therapy (sitagliptin followed by liraglutide) compared to insulin following treatment with pasireotide.
This phase I/II clinical research trial will test the hypothesis that repeated dosing of of intra-arterial Bevacizumab at 15 mg/kg can be safely administered to enhance survival of subjects with newly diagnosed Glioblastoma multiforme while they receive standard of care. We expect that this project will provide important information regarding the utility of repeated SIACI Bevacizumab therapy for newly diagnosed malignant glioma, and may alter the way these drugs are delivered to our patients in the future.
This phase I/II clinical research trial will test the hypothesis that repeated direct intraarterial infusion Bevacizumab (15mg/kg) can be safely administered to enhance survival of patients with relapsed/refractory Glioblastoma Multiforme and Anaplastic Astrocytoma. The current standard of care for recurring GBM is for patients to receive Bevacizumab (Avastin) intravenously (IV) at 10mg/kg every two weeks until their tumor grows more than 25%. This study will help investigators determine if IV therapy with Bevacizumab should be combined with repeated selected intra-arterial Bevacizumab to improve progression free and overall survival.
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
PI: John Boockvar, MD
Co-PI: Peter Costantino, MD and Dennis Kraus, MD
This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC). Cetuximab has recently emerged as a promising biological agent in the management of HNSCC. It is an epidermal growth factor receptor (EGFR) inhibitor which increases the radiosensitivity of tumors to radiotherapy (RT), and has been proven to be effective. A large body of evidence supports the theoretical attractiveness of intra-arterial chemotherapy, related to the first pass of the drug through the tumor bed and to the possibility of increasing the doses of the chemotherapeutic agent, thus minimizing systemic toxic side effects. Theoretically, a higher dose of Cetuximab saturating the tumor tissue’s EGFR receptor will increase its responsiveness with or without concurrent radiation therapy.
Co-PI: Jonathan Knisely, MD
The purpose of this study is to evaluate the safety of administering a single dose of trastuzumab into your artery for the treatment of your brain metastasis(es) from HER2/neu positive breast cancer. This study will try to determine the best tolerated single dosage of trastuzumab administered into arteries by gradually increasing the dosage given to participants as the study progresses. Early participants will receive a dosage of 1 mg/kg. As more participants enroll into the study, this single dosage will be increased at designated levels up to 8 mg/kg, if it’s determined to be safe to increase. Trastuzumab is a type of antibody, which is a protein used by the body’s immune system to fight against pathogens such as bacteria and viruses. This antibody binds to cell receptors known as the HER2/neu tyrosine kinase receptor. These receptors are expressed in certain cancer subtypes such as breast cancer. By blocking signaling through this HER2/neu receptor, trastuzumab can slow down or stop the over-expression of the HER2/neu protein. Over-expression of HER2/neu has been shown to play a role in the development and progression of certain types of breast cancer. Therefore, by slowing down or stopping the expression of HER2/neu, we hope to slow down or stop the growth of your metastasis(es) and increase the responsiveness to therapy.
PI: John Boockvar, MD
The purpose of this study is to determine if the investigational products, Toca 511 and Toca FC, as a combination treatment is effective (works) and safe, compared to a selected number of approved treatments for brain tumors, called a control treatment. Toca 511 is a live virus that has been built to carry a gene into cancer cells. This gene carries instructions that cause the cancer cells to turn Toca FC into a drug that may kill the cancer cells. Toca FC is an investigational extended-release form of flucytosine (5-FC). Flucytosine is a drug approved to treat fungal infections; however, it is not approved for the treatment of brain tumors. This study will examine progression free survival with treatment with either Toca 511 and Toca FC combination treatment or the control treatment, and overall survival.
Neutrophil-Guided Drug Delivery for Targeting Residual Glioma Cells. Schneider JR, Kwan K, Boockvar JA. Neurosurgery. 2018 Jan 1
Lesional Temporal Lobe Epilepsy: Beware the Deceitful "Panic Attack". Kulason KO, Schneider JR, Rahme R, Pramanik B, Chong D, Boockvar JA. World neurosurgery. 2017 Dec 27
Use of HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells as a Potential Therapeutic for Progressive HER2-Positive Glioblastoma. Schneider JR, Kwan K, Boockvar JA. Neurosurgery. 2017 Nov 1
FTY720/fingolimod, an oral S1PR modulator, mitigates radiation induced cognitive deficits. Stessin AM, Banu MA, Clausi MG, Berry N, Boockvar JA, Ryu S. Neuroscience letters. 2017 Sep 29
Colony Stimulating Factor-1 Receptor Inhibitors-A 4 for 1 Deal in the Desire to Improve Glioma Radiotherapy. Skeie B, Ruggieri R, Boockvar JA, Symons M. Neurosurgery. 2017 Sep 1
Management of Tiny Meningiomas: To Resect or Not Resect. Schneider JR, Kulason KO, White T, Pramanik B, Chakraborty S, Heier L, Ray AE, Anderson TA, Chong DJ, Boockvar J. Cureus. 2017 Jul 25
Do craniopharyngioma molecular signatures correlate with clinical characteristics? Omay SB, Chen YN, Almeida JP, Ruiz-Treviño AS, Boockvar JA, Stieg PE, Greenfield JP, Souweidane MM, Kacker A, Pisapia DJ, Anand VK, Schwartz TH. Journal of neurosurgery. 2017 Jul 14
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma. Alter RA, White TG, Fanous AA, Chakraborty S, Filippi CG, Pisapia DJ, Tsiouris AJ, Boockvar JA J Exp Ther Oncol. 2017 May
Use of Chimeric Antigen Receptor T Cells as a Potential Therapeutic for Glioblastoma. Babar Khan M, Chakraborty S, Boockvar JA. Neurosurgery. 2017 May 1
Radiation Exposure and Safety Precautions Following 131Cs Brachytherapy in Patients with Brain Tumors. Yondorf MZ, Schwartz TH, Boockvar JA, Pannullo S, Stieg P, Sabbas A, Pavese A, Trichter S, Nedialkova L, Parashar B, Nori D, Chao KS, Wernicke AG. Health Phys. 2017 Apr
Frameless and Maskless Stereotactic Navigation with a Skull-Mounted Tracker:A Technical Report. Fanous AA, White TG, Hirsch MB, Chakraborty S, Costantino PD, Langer DJ, Boockvar JA. World Neurosurg. 2017 Mar 11
Effect of Whole Brain Radiation Therapy on Cognitive FunctionSchneider JR, Chakraborty S, Boockvar JA. Neurosurgery. 2017 Mar 1
Glioblastoma spheroids produce infiltrative gliomas in the rat brainstem. Zhou Z, Luther N, Singh R, Boockvar JA, Souweidane MM, Greenfield JP. Childs Nerv Syst. 2017 Feb 24
Curcumin changes the polarity of tumor-associated microglia and eliminates glioblastoma. Mukherjee S, Baidoo J, Fried A, Atwi D, Dolai S, Boockvar J, Symons M, Ruggieri R, Raja K, Banerjee P. Int J Cancer. 2016 Dec 15
Gross Total Resection of Glioblastoma Improves Overall Survival and Progression-Free Survival Compared to Subtotal Resection or Biopsy Alone. Khan MB, Chakraborty S, Boockvar JA. Neurosurgery. 2016 Dec
Intra-arterial cetuximab for the treatment of recurrent unresectable head and neck squamous cell carcinoma. Tham T, White TG, Chakraborty S, Lall RR, Ortiz R, Langer DJ, Shatzkes D, Filippi CG, Kraus D, Boockvar JA, Costantino PD. J Exp Ther Oncol. 2016 Nov
Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma. Chakraborty S, Filippi CG, Burkhardt JK, Fralin S, Ray A, Wong T, Ortiz R, Langer DJ, Boockvar JA. J Exp Ther Oncol. 2016 Nov
Transdifferentiation-Induced Neural Stem Cells for the Treatment of Malignant Gliomas. Chakraborty S, Schneider J, Boockvar JA. Neurosurgery. 2016 Oct
Transdifferentiation Induced Neural Stem Cells for the Treatment of Malignant Gliomas. Chakraborty S, Schneider J, Boockvar JA. Neurosurgery. 2016 Aug
Erratum to: Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. Chakraborty S, Filippi CG, Wong T, Ray A, Fralin S, Tsiouris AJ, Praminick B, Demopoulos A, McCrea HJ, Bodhinayake I, Ortiz R, Langer DJ, Boockvar JA. J Neurooncol. 2016 Jul
Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. Chakraborty S, Filippi CG, Wong T, Ray A, Fralin S, Tsiouris AJ, Praminick B, Demopoulos A, McCrea HJ, Bodhinayake I, Ortiz R, Langer DJ, Boockvar JA. J Neurooncol. 2016 Jul
The FIRST Trial: Implications for Neurosurgery. Chakraborty S, Schulder M, Boockvar JA. Neurosurgery. 2016 Jun
Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy. Singh R, Kesavabhotla K, Kishore SA, Zhou Z, Tsiouris AJ, Filippi CG, Boockvar JA, Kovanlikaya I. AJNR Am J Neuroradiol. 2016 May 26
Neuro-oncology biotech industry progress report. Chakraborty S, Bodhinayake I, Chiluwal A, Langer DJ, Ruggieri R, Symons M, Boockvar JA. J Neurooncol. 2016 May
Anterior Cervical Discectomy and Fusion (ACDF): Comparison Between Zero Profile Implants and Anterior Cervical Plate and Spacer. Alimi M, Njoku I, Hofstetter CP, Tsiouris AJ, Kesavabhotla K, Boockvar J, Navarro-Ramirez R, Härtl R. Cureus. 2016 Apr 17;8(4)
Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy. Singh R, Kesavabhotla K, Kishore SA, Zhou Z, Tsiouris AJ, Filippi CG, Boockvar JA, Kovanlikaya I. AJNR Am J Neuroradiol. 2016 May 26.
Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. Chakraborty S, Filippi CG, Wong T, Ray A, Fralin S, Tsiouris AJ, Praminick B, Demopoulos A, McCrae H, Bodhinayake I, Ortiz R, Langer DJ, Boockvar JA.J Neurooncol. 2016 Mar 5.
Neuro-oncology biotech industry progress report.Chakraborty S, Bodhinayake I, Chiluwal A, Langer DJ, Ruggieri R, Symons M, Boockvar JA.J Neurooncol. 2016 Feb 20. [Epub ahead of print]
The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors.Wernicke AG, Yondorf MZ, Parashar B, Nori D, Clifford Chao KS, Boockvar JA, Pannullo S, Stieg P, Schwartz TH.J Neurooncol. 2016 Jan 2.
Magnetic Resonance Imaging to Identify Glioblastoma Molecular Phenotypes.Chakraborty S, Priamo F, Boockvar JA.Neurosurgery. 2016 Feb;78(2):N20-1. doi: 10.1227/01.neu.0000479895.10242.9d.
Multiportal Combined Transorbital and Transnasal Endoscopic Resection of Fibrous Dysplasia. Tham T, Costantino PD, Bruni M, Langer D, Boockvar J, Singh P [published online Oct 25 2015]. J Neurol Surg Rep. 2015. doi: 10.1055/s-0035-1566126
Repurposing mebendazole for the treatment of medulloblastoma. Bodhinayake I, Symons M, Boockvar JA. Neurosurgery. 2015 Feb;76(2):N15-6.doi:10.1227/01.neu.0000460594.93803.cb.No
Toxin-secreting implantable therapeutic stem cells. Gamble AJ, Boockvar JA. Neurosurgery. 2015 Apr;76(4):N16-8.
Isolated cortical vein thrombosis: case series. Singh R, Cope WP, Zhou Z, De Witt ME, Boockvar JA, Tsiouris AJ. J Neurosurg. 2015 Aug;123(2):427-33. doi: 10.3171/2014.9.JNS141813. Epub 2015 Mar 20.PMID: 25794339
A New Tool in Defining Disease Progression in Glioblastoma. De Witt ME, Boockvar JA. Neurosurgery. 2015 Aug;77(2):N13-5. doi: 10.1227/01.neu.0000467293.33634.17. No abstract available
Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling. Gürsel DB, Banu MA, Berry N, Marongiu R, Burkhardt JK, Kobylarz K, Kaplitt MG, Rafii S, Boockvar JA. J Neurooncol. 2015 Jan;121(1):19-29. doi: 10.1007/s11060-014-1602-3. Epub 2014 Oct 26.
Multifunctionalization of cetuximab with bioorthogonal chemistries and parallel EGFR profiling of cell-lines using imaging, FACS and immunoprecipitation approaches. Reschke ME, Uprety R, Bodhinayake I, Banu M, Boockvar JA, Sauve AA. Biochim Biophys Acta. 2014 Aug 1. pii: S1570-9639(14)00195-2. doi: 10.1016/j.bbapap.2014.07.017. [Epub ahead of print]
Novel hydrogel application in minimally invasive surgical approaches to spontaneous intracranial hypotension. Chai CM, Banu MA, Cobb W, Mehta N, Heier L, Boockvar JA. J Neurosurg. 2014 Aug 1:1-7. [Epub ahead of print]
Targeting a Heterogeneous Tumor: The Promise of the Interleukin-13 Receptor α2. Bodhinayake I, Ottenhausen M, Boockvar JA. Neurosurgery. 2014 Aug;75(2):N18-9. doi: 10.1227/01.neu.0000452316.07108.d2. No abstract available.
Prophylactic plastic surgery closure of neurosurgical scalp incisions reduces the incidence of wound complications in previously-operated patients treated with bevacizumab (Avastin®) and radiation. Golas AR, Boyko T, Schwartz TH, Stieg PE, Boockvar JA, Spector JA. J Neurooncol. 2014 May 29. [Epub ahead of print
Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases. Wernicke AG, Yondorf MZ, Peng L, Trichter S, Nedialkova L, Sabbas A, Kulidzhanov F, Parashar B, Nori D, Clifford Chao KS, Christos P, Kovanlikaya I, Pannullo S, Boockvar JA, Stieg PE, Schwartz TH.J Neurosurg. 2014 Aug;121(2):338-48. doi: 10.3171/2014.3.JNS131140. Epub 2014 May 2.
The only way out is in: a deeper understanding of anti-VEGF therapy escape mechanisms offers possibilities for more effective antiangiogenic treatment. Ottenhausen M, Bodhinayake I, Boockvar JA. Neurosurgery. 2013 Dec
Results and risk factors for recurrence following endoscopic endonasal transsphenoidal surgery for pituitary adenoma. Bodhinayake I, Ottenhausen M, Mooney MA, Kesavabhotla K, Christos P, Schwarz JT, Boockvar JA. Clin Neurol Neurosurg. 2014 Apr
VIGAS and Beyond: The Impact of HCMV-Infection and Its Treatment in Glioblastoma. Ottenhausen M, Bodhinayake I, Schaefer PM, Boockvar JA. Neurosurgery. 2014 Apr
Expanding the borders: the evolution of neurosurgical approaches. Ottenhausen M, Bodhinayake I, Evins AI, Banu M, Boockvar JA, Bernardo A. Neurosurg Focus. 2014 Apr
Conservative management of cavernous sinus cavernous hemangioma in pregnancy. Haber JS, Kesavabhotla K, Ottenhausen M, Bodhinayake I, Dinkin MJ, Segal AZ, Lee YM, Boockvar JA.J Neurosurg. 2014 Apr 11
Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Infanger DW, Cho Y, Lopez BS, Mohanan S, Liu SC, Gursel D, Boockvar JA, Fischbach C. Cancer Res. 2013 Oct 11
A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Kast RE, Boockvar JA et al. Oncotarget. 2013 April
Industry progress report on neuro-oncology: Biotech update 2013.Ottenhausen M, Bodhinayake I, Banu M, Kesavabhotla K, Ray A, Boockvar JA. J Neurooncol. 2013 Aug 16
Trials and tribulations of cancer immunotherapy: the dendritic cell vaccine shows promise in a phase I glioblastoma multiforme trial. Gürsel DB, Schlaff CD, Boockvar JA. Neurosurgery. 2012 Dec
Zero-profile Anchored Spacer Reduces Rate of Dysphagia Compared to ACDF With Anterior Plating. Hofstetter CC, Kesavabhotla K, Boockvar JA. J Spinal Disord Tech. 2013 Feb 19
Industry progress report on neuro-oncology: a biotech update. Haber JS, Banu MA, Ray A, Kesavabhotla K, Boockvar JA. J Neurooncol. 2013 Feb 20. [Epub ahead of print] PubMed PMID: 23423513.
Endoscopic endonasal transphenoidal surgery using BrainLAB headband for navigation without rigid fixation. Duque, Sara G, Gorrepati, Ramana, Kesavabhotla, K, Boockvar, JA. Journal of Neurological Surgery – Part A February 16, 2012 Manuscript ID: CEN-2012-02-OA-0607
EGFR Targeted Inhibition Resistance: Compensatory Activation of ERBB Family Members in Glioblastoma Cancer Stem-Like Cells Promotes Proliferation. Gursel DB, Boockvar JA, Schlaff, CD. Neurosurgery. 2012 Oct; 71(4):N17-18. PMID:22989968 [PubMed - in process]
Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance, Epidemiology, and End Results (SEER)-based analysis. Stessin AM, Schwartz A, Judanin G, Pannullo SC, Boockvar JA, Schwartz TH, Stieg PE, Wernicke AG. J Neurosurg. 2012 Aug 17. [Epub ahead of print]PMID:22900840[PubMed - as supplied by publisher]
Getting a neural stem cell from a fibroblast. Berry N, Gursel DB, Boockvar JA. Neurosurgery. 2012 Aug;71(2):N26-8. No abstract available. PMID:22811206[PubMed - in process]
Resetting the stem cell clock: impact of the systemic milieu on oligodendrocyte precursor cell differentiation and remyelination. Banu MA, Alter R, Boockvar JA. Neurosurgery. 2012 Jun;70(6):N15-7. No abstract available.
Therapeutic stem cells encapsulated in a synthetic extracellular matrix selectively kill tumor cells, delay tumor growth, and increase survival in a mouse resection model of malignant glioma. Gursel DB, Berry N, Boockvar JA. Neurosurgery. 2012 Jun;70(6):N17-9. No abstract available. PMID:22596007[PubMed - in process]
FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells. Stessin AM, Gursel DB, Schwartz A, Parashar B, Kulidzhanov FG, Sabbas AM, Boockvar J, Nori D, Wernicke AG. Neurosci Lett. 2012 May 16;516(2):253-8. Epub 2012 Apr 7.PMID:22507238
Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: From bedside to bench. Burkhardt JK, Hofstetter CP, Santillan A, Shin BJ, Foley CP, Ballon DJ, Pierre Gobin Y, Boockvar JA. J Clin Neurosci. 2012 Nov;19(11):1568-72. doi: 10.1016/j.jocn.2012.03.012. Epub 2012 Sep 15. PubMed PMID: 22985932.
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. Kesavabhotla K, Schlaff CD, Shin B, Mubita L, Kaplan R, Tsiouris AJ, Pannullo SC, Christos P, Lavi E, Scheff R, Boockvar JA. J Exp Ther Oncol. 2012;10(1):71-81.PMID:22946346[PubMed - in process]
Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2. Riina HA, Burkhardt JK, Santillan A, Bassani L, Patsalides A, Boockvar JA. Interv Neuroradiol. 2012 Jun;18(2):127-32. Epub 2012 Jun 4.PMID:22681725[PubMed - in process]
Metabolic Response of Glioblastoma to Superselective Intra-Arterial Cerebral Infusion of Bevacizumab: A Proton Magnetic Resonance Spectroscopic Imaging Study. Jeon JY, Kovanlikaya I, Boockvar JA, Mao X, Shin B, Burkhardt JK, Kesavabhotla K, Christos P, Riina H, Shungu DC, Tsiouris AJ. AJNR Am J Neuroradiol. 2012 May 10. [Epub ahead of print]PMID:22576886
Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model. Burkhardt JK, Santillan A, Hofstetter CP, Christos P, Berry N, Shin BJ, Foley CP, Gürsel DB, Ballon DJ, Gobin YP, Boockvar JA. J Exp Ther Oncol. 2012;10(1):31-7.PMID:22946342
Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma. Rajappa P, Krass J, Riina HA, Boockvar JA, Greenfield JP. Interv Neuroradiol. 2011 Dec;17(4):459-65. Epub 2011 Dec 16. PubMed PMID: 22192550.
Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series. Shin BJ, Burkhardt JK, Riina HA, Boockvar JA. Neurosurg Clin N Am. 2012 Apr;23(2):323-9. Epub 2012 Feb 18. PubMed PMID: 22440875.
Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. Hofstetter CP, Burkhardt JK, Shin BJ, Gürsel DB, Mubita L, Gorrepati R, Brennan C, Holland EC, Boockvar JA. PLoS One. 2012;7(1):e30059. Epub 2012 Jan 11. PubMed PMID: 22253878; PubMed Central PMCID: PMC3256196.
The contribution of Notch signaling to glioblastoma via activation of cancer stem cell self-renewal: the role of the endothelial network. Gürsel DB, Berry N, Boockvar JA. Neurosurgery. 2012 Feb;70(2):N19-21. PubMed PMID: 22251985.
Dissecting the Perivascular Stem-Cell Niche: Can We Take Tumor Recurrence Down a NOTCH? Banu MA, Shin BJ, Boockvar JA. Neurosurgery. 2012 Apr;70(4):N18-9. PubMed PMID: 22426056.
Notch Inhibition via Micro-RNA Blocks Glioma Development. Berry N, Gursel DB, Boockvar JA. Neurosurgery. 2012 Apr;70(4):N20-2. PubMed PMID: 22426058.
Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, Tsiouris AJ, Boockvar JA. World Neurosurg. 2012 Jan;77(1):130-4. Epub 2011 Nov 21. PubMed PMID: 22405392.
Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme. Burkhardt JK, Shin BJ, Schlaff CD, Riina H, Boockvar JA. J Exp Ther Oncol. 2011;9(3):183-6. PubMed PMID: 22070049.
Neural stem cells and glioma stem-like cells respond differently to chemotherapeutic drugs: selectivity at the cellular level. Burkhardt JK, Shin BJ, Boockvar JA. Neurosurgery. 2011 Jun;68(6):N21-2. PubMed PMID: 21778947.
Direct conversion of human fibroblasts to functional neurons in one step. Berry N, Gursel DB, Boockvar JA. Neurosurgery. 2011 Dec;69(6):N18-9. PubMed PMID: 22067346.
Endovascular embolization of cervical hemangiopericytoma with Onyx-18: case report and review of the literature. Santillan A, Zink W, Lavi E, Boockvar J, Gobin YP, Patsalides A. J Neurointerv Surg. 2011 Sep;3(3):304-7. Epub 2010 Dec 8. PubMed PMID: 21990849.
Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA. Interv Neuroradiol. 2011 Sep;17(3):286-95. Epub 2011 Oct 17. PubMed PMID: 22005689
Glioblastoma Multiforme Stem-Like Cells and Hypoxia: The Novel Role of HAF. Shin B, Burkhardt JK, Boockvar J. Neurosurgery. 2011 Oct;69(4):N21. PubMed PMID: 21900808.
Glioblastoma Stem-Like Cells-Biology and Therapeutic Implications. Gürsel DB, Shin BJ, Burkhardt JK, Kesavabhotla K, Schlaff CD, Boockvar JA. Cancers (Basel). 2011 Jun 10;3(2):2655-2666. PubMed PMID: 21796273; PubMed Central PMCID: PMC3142771.
Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas. Hofstetter CP, Shin BJ, Mubita L, Huang C, Anand VK, Boockvar JA, Schwartz TH. Neurosurg Focus. 2011 Apr;30(4):E10. PubMed PMID: 21456921.
Optimization of glioblastoma multiforme stem cell isolation, transfection, and transduction. Gürsel DB, Beyene RT, Hofstetter C, Greenfield JP, Souweidane MM, Kaplitt M, Arango-Lievano M, Howard B, Boockvar JA. J Neurooncol. 2011 Sep;104(2):509-22. Epub 2011 Feb 19. PubMed PMID: 21336775.)
Generation of neural stem cells: a team approach. Hofstetter C, Boockvar J. Neurosurgery. 2010 Dec;67(6):N22-3. PubMed PMID: 21107172.
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, Seedial SM, Pannullo SC, Schwartz TH, Stieg P, Zimmerman RD, Knopman J, Scheff RJ, Christos P, Vallabhajosula S, Riina HA. Clinical article. J Neurosurg. 2011 Mar;114(3):624-32. Epub 2010 Oct 22. PubMed PMID: 20964595.
Interstitial infusion of erlotinib in the rodent brain. Luther N, Karampelas I, Souliopoulos EP, Edgar MA, Boockvar JA, Souweidane MM. J Exp Ther Oncol. 2009;8(2):79-84. PubMed PMID: 20192114.
EGFR signaling is differentially activated in patient-derived glioblastoma stem cells. Howard BM, Gursel DB, Bleau AM, Beyene RT, Holland EC, Boockvar JA. J Exp Ther Oncol. 2010;8(3):247-60. PubMed PMID: 20734923.
Neural stem cells: targeting glioma in 3-dimensions. Hofstetter CP, Boockvar JA. Neurosurgery. 2010 Jun;66(6):N15. PubMed PMID: 20495412.
Pineal parenchymal tumor of intermediate differentiation with papillary features: a continuum of primary pineal tumors? Cohan JN, Moliterno JA, Mok CL, Lavi E, Boockvar JA. J Neurooncol. 2011 Jan;101(2):301-6. Epub 2010 Jun 3. PubMed PMID: 20521161.
High-viscosity polymethylmethacrylate cement for endoscopic anterior cranial base reconstruction. Moliterno JA, Mubita LL, Huang C, Boockvar JA. J Neurosurg. 2010 Nov;113(5):1100-5. Epub 2010 Mar 26. PubMed PMID: 20345225.
Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Riina HA, Knopman J, Greenfield JP, Fralin S, Gobin YP, Tsiouris AJ, Souweidane MM, Boockvar JA. Interv Neuroradiol. 2010 Mar;16(1):71-6. Epub 2010 Mar 25. PubMed PMID: 20377982.
Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. Riina HA, Fraser JF, Fralin S, Knopman J, Scheff RJ, Boockvar JA. J Exp Ther Oncol. 2009;8(2):145-50. PubMed PMID: 20192120.
Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection. Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, Ivanidze J, Moliterno JA, Parashar B, Trichter S, Sabbas AM, Nori D. J Cancer Res Ther. 2010 Jan-Mar;6(1):65-74. PubMed PMID: 20479550.
Forcing tumor stem cells to an end. Hofstetter CP, Boockvar JA. Neurosurgery. 2010 Apr;66(4):N17-8. PubMed PMID: 20305479.
Stem cell based growth factory delivery to the injured spinal cord. Boockvar JA, Hofstetter CP. Neurosurgery, 2010 Feb;66(2): N16-7
Tubular microsurgery for lumbar discectomies and laminectomies in obese patients; operative results and outcome. Tomasino A, Parikh K, Steinberger J, Knopman J, Boockvar JA, Hartl R. Spine. (Phila Pa 1976). 2009 Aug 15;34(18): E664-72.
Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. Riina HA, Fraser JF, Fralin S, Knopman J, Scheff RJ, Boockvar JA. J Exp Ther Oncol. 2009;8(2):145-50. PubMed PMID: 20192120.
Reduction of seizures by transplantation of embryonic GABAergic interneurons into Kv1.1 mutant mice. Hofstetter C, Boockvar J. Neurosurgery. 2009 Dec;65(6):N8-9. PubMed PMID: 19934957
Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. Ayuso-Sacido A, Moliterno JA, Kratovac S, Kapoor GS, O'Rourke DM, Holland EC, García-Verdugo JM, Roy NS, Boockvar JA. J Neurooncol. 2010 May;97(3):323-37. Epub 2009 Oct 24. PubMed PMID: 19855928.
The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study. Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, Moliterno JA, Ivanidze J, Trichter S, Sabbas AM, Parashar B, Nori D. Brachytherapy. 2010 Jan-Mar;9(1):91-9. Epub 2009 Oct 21. PubMed PMID: 19850535.
Stem cell populated implanted trachea. Beyene R, Howard BM, Boockvar JA. Neurosurgery. 2009 May;64(5):N12-3. PubMed PMID: 19404132
Transformation of a low-grade pineal parenchymal tumour to secondary pineoblastoma. Howard BM, Hofstetter C, Wagner PL, Muskin ET, Lavi E, Boockvar JA. Neuropathol Appl Neurobiol. 2009 Apr;35(2):214-7. PubMed PMID: 19284482
Novel Treatment of Glioblastoma Multiforme Tumor Stem Cells with Oncolytic Viruses. Beyene, R., Boockvar, JA. July 2009: 65:1 Neurosurgery
Combined supraciliary and endoscopic endonasal approach for resection of frontal sinus mucoceles: technical note. Knopman J, Sigounas D, Huang C, Kacker A, Schwartz TH, Boockvar JA. Minim Invasive Neurosurg. 2009 Jun;52(3):149-51. Epub 2009 Jul 31. PubMed PMID: 19650020.
Tumor stem cells: will understanding a new paradigm lead to improved therapies? Howard B, Boockvar JA. Brain Expert Rev. Neurotherapeutics 8(4), 159-160 (2008)
Operative Results and Learning Curve with Microscope-Assisted Tubular Microsurgery for one and two discectomies and laminectomy. Parikh K, Tomasino A, Knopman J, Boockvar JA, Hartl R. Neurosurg Focus, 25, 2: 1-6 2008
Results and risk factors for recurrence following single-level tubular lumbar microdiscectomy. Moliterno JA, Knopman J, Parikh K, Cohan JN, Huang QD, Aaker GD, Grivoyannis AD, Patel AR, Härtl R, Boockvar JA. J Neurosurg Spine. 2010 Jun;12(6):680-6. PubMed PMID: 20515355.
Disease-specific induced pluripotent stem cells. Beyene R, Boockvar JA. Neurosurgery. 2008; 63(6):12
Stem Cell migration in a novel model to study pediatric brain tumors. Greenfield JP, Boockvar JA. Neurosurgery. 2008 Aug;63(2): N9
Endoscopic Endonasal Transsphenoidal Surgery using a Skull Reference Array and Laser Surface Scanning. Greenfield JP, Howard BM, Huang C, Boockvar JA. Minimally Invasive Neurosurgery. 51: 244-246. 2008.
Magnetic Resonance Spectroscopy Traces Neural Progenitor Cells in Vivo. Howard B, Boockvar JA. Neurosurgery. 2008 Apr: 62(4):N12
Pluripotential stem cells from mature somatic cells. Howard BM, Boockvar JA, Dunn IF, Friedlander RM. Neurosurgery. 2008 Feb; 62 (2): N6-7.
Long-term expansion of adult human brain subventricular zone precursors. Ayuso-Sacido A, Roy NS, Schwartz TH, Greenfield JP, Boockvar JA. Neurosurgery. 2008 Jan;62(1):223-9; discussion 229-31. doi: 10.1227/01.NEU.0000311081.50648.4C. PubMed PMID: 18300911
Use of human neural tissue for the generation of progenitors. Greenfield JP, Ayuso-Sacido A, Schwartz TH, Pannullo S, Souweidane M, Stieg PE, Boockvar JA. Neurosurgery. 2008 Jan;62(1):21-37; discussion 27-30. doi: 10.1227/01.NEU.0000311059.87873.46. Review. PubMed PMID: 18300889.
Assessing neural stem cell motility using an agarose gel based microfluidic device. Wong K, Ayuso-Sacido A, Anhow P, Boockvar JA and Wu M., Journal of Visualized Experiments, Vol 1, 2008
A new strategy for analysis of phenotypic marker antigens in murine and human brain tumor derived neurospheres, Bleau A, Howard, B, Taylor L, Gursel D, Tung L, Greenfield, J, Holland EC, Boockvar, JA. Neurosurg Focus, 24 1-9, March/April 2008
SPORTing Statistics: Slicing the Drive on Appropriate Treatment. Fraser, J., Hartl, R., Boockvar, JA. Neurology Alert, vol 2, 9-12, 2007
Intervertebral Disc Transplantation: Treatment in Motion. Fraser, J., Hartl, R., Boockvar, JA. Neurology Alert, vol 4, 20-22, 2007
Cell enhancer or cell transformer? Ayuso, A., Greenfield JP., Graham, C., Boockvar, JA. The duality of EGFR signaling and neural stem cell phenotype: Current Stem Cell Research and Therapy, 2: 231-238, 2006
Experimental traumatic brain injury modulates the survival, migratory and terminal phenotype of transplanted EGFR activated neural stem cells. Boockvar JA, Schouten J, Royo N, Millard M, Spangler Z, Castelbuono D, Snyder E, O’Rourke D, McIntosh T. Neurosurgery 56: 163-71, 2005
Dural Cavernous angioma of the posterior sagittal sinus. Boockvar JA, Stiefel M, Malhotra N, Dolinskas C, Dwyer-Joyce C, LeRoux PD: case report. Surgical Neurology 63: 178-181, 2005
Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Boockvar JA, Kapitonov D, Schouten J, Counelis GJ, Kapoor G, Bogler O, Snyder E, McIntosh T, O’Rourke DM. Molecular and Cellular Neuroscience 24, (4): 1116-1130, 2003
Neural stem cell biology may be well suited for improving brain tumor therapies. Yip S, Aboody KS, Burns M, Imitola J, Boockvar JA, Allport J, Park KI, Teng YD, Lachyankar M, McIntosh T, O'Rourke DM, Khoury S, Weissleder R, Black PM, Weiss W, Snyder EY. Cancer J 9(3):189-204, 2003
Transplanted neural stem cells survive, differentiate and improve neurologic motor function after experimental traumatic brain injury. Riess P, Zhang C, Saatman K, Laurer HL, Teng T, Bareyre FM, Raghupathi R, Lenzlinger P, Longhi L, Lifshitz J, Neugebauer E, Boockvar JA, Snyder E, McIntosh TK. Neurosurgery 51 (4): 1-11, 2002
Congenital cervical spinal stenosis and sports-related cervical cord neurapraxia in children. Boockvar JA, Durham S, Sun P. Spine 26 (24): 2709-2712, 2001
The development of the Spitz-Holter valve in Philadelphia. Boockvar JA, Loudon W, Sutton LN. Journal of Neurosurgery 95: 145-147, 2001
Surgical management of cubital tunnel syndrome. Boockvar JA, Zager EL: In Thieme’s (ed): Seminars in Neurosurgery, Vol. 12 (1): 57-63, 2001
Results and risk factors for anterior cervicothoracic junction surgery. Boockvar JA, Phillips MF, Telfeian AE, O’Rourke D, Marcotte PJ. Journal of Neurosurgery Spine 94: 12-17, 2001
Long-term deep brain stimulation in a patient with essential Tremor: clinical response and postmortem correlation with stimulator termination sites in ventral thalamus. Boockvar JA, Telfeian AE, Baltuch GH, Skolnick B, Simuni T, Stern M, Schmidt L, Trojanowski JQ.: Journal of Neurosurgery 93: 140-144, 2000
Efficacy of unilateral deep brain stimulation of the VIM nucleus of the thalamus in a patient with bipolar disorder associated with Klinefelter’s syndrome and essential tremor. Telfeian AE, Boockvar JA, Simuni T, Jaggi J, Skolnick B, Baltuch GH: Journal of Neurosurgery 93: 127-128, 2000
Symptomatic lateral ventricular ependymal cysts: Criteria for distinguishing these rare cysts from other symptomatic cysts of the ventricles. Boockvar JA, Shafa B, Forman M, O’Rourke D.: Case Report. Neurosurgery 46(5): 1229-1233, 2000
Neurosurgery at the University of Pennsylvania Medical Center. Boockvar JA, Virella A, Kotapka M, Flamm ES, Grady MS.: Neurosurgery 46 (5): 1223-1228, 2000
Post-traumatic meningioma: case report and historical perspective. Boockvar JA, Kotzen RA, Swanson R, Milhorat TH. J Neurol Neurosurg Psych 66: 796-798, 1999
Subacute paraparesis induced by venous thrombosis of a spinal angiolipoma. Boockvar JA, Black K, Malik S, Stanek A, Tracey KJ.: Spine 22:2304-2308, 1997